| Literature DB >> 34192197 |
Jakob Peter Armann1, Carolin Kirsten1, Lukas Galow1, Elisabeth Kahre1, Luise Haag1, Alexander Dalpke2, Christian Lück2, Reinhard Berner1.
Abstract
Objective: To quantify the number of undetected SARS-CoV-2 infections in educational settings. Design: Serial SARS-CoV-2 seroprevalence study before and during the second wave of the COVID-19 pandemic. Setting: Secondary school in Dresden, Germany. Participants: Grade 8-12 students and their teachers were invited to participate in serial blood sampling and SARS-CoV-2 IgG antibody assessment. Main outcome measure: Seroprevalence of SARS-CoV-2 antibodies in study population.Entities:
Keywords: COVID-19; epidemiology
Mesh:
Year: 2021 PMID: 34192197 PMCID: PMC7992381 DOI: 10.1136/bmjpo-2021-001036
Source DB: PubMed Journal: BMJ Paediatr Open ISSN: 2399-9772
Demographic data
| First study visit (November 2020) | Second study visit (December 2020) | |||
| Students | Teachers | Students | Teachers | |
| Participants | 247 (82%) | 55 (18%) | 197 (85%) | 40 (15%) |
| Proportion of all eligible students/teachers | 246/464 (53%) | 55/70 (79%) | 197/464 (42%) | 40/70 (51%) |
| New participants at second visit | – | – | 17 | 1 |
| Age (median) | 15 (14–17) | 51 (44–56) | 16 (14–17) | 52 (42–57) |
| Female | 131 (53%) | 33 (66%) | 109 (57%) | 23 (64%) |
| Household size | 4 (4–5) | 3 (2–4) | 3 (3–5) | 3 (2–3) |
SARS-CoV-2 seroprevalence
| First study visit (November 2020) | Second study visit (December 2020) | |
| Seroprevalence % (CI) | 1.7 (0.3 to 3.3) | 6.8 (3.8 to 10.1) |
| Seroprevalence % (CI)—for participants with two samples available | 5.5 (2.3 to 8.7) | |
| Number of participants who reported cold-like symptoms between study visits | 92 | |
| Seroprevalence % (CI)—for participants with cold-like symptoms | 7.6 (3.3 to 13.0) | |
| Seroprevalence % (CI)—for participants without cold-like symptoms | 6.2 (2.8 to 10.3) | |
| Ratio of undetected to detected cases | 1/4 (0.25) | 4/12 (0.33) |
| Ratio of undetected to detected cases in participants with mandated quarantine measures between visits | 1/4 (0.25) |